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Objective: The Web-based distress management program for patients with an implantable cardioverter-deﬁbrillator (ICD;
WEBCARE) was developed to mitigate distress and enhance health-related quality of life in ICD patients. This study investigated the
treatment effectiveness at 3-month follow-up for generic and disease-speciﬁc outcome measures. Methods: Consecutive patients
implanted with a ﬁrst-time ICD from six hospitals in the Netherlands were randomized to either the ‘‘WEBCARE’’ or the ‘‘usual care’’
group. Patients in the WEBCARE group received a 12-week ﬁxed, six-lesson behavioral treatment based on the problem-solving
principles of cognitive behavioral therapy. Results: Two hundred eighty-nine patients (85% response rate) were randomized. The
prevalence of anxiety and depression ranged between 11% and 30% and 13% and 21%, respectively. No signiﬁcant intervention effects
were observed for anxiety (A = 0.35; p = .32), depression (A = j0.01; p = .98) or health-related quality of life (Mental Component
Scale: A = 0.19; p = .86; Physical Component Scale: A = 0.58; p = .60) at 3 months, with effect sizes (Cohen d) being small (range,
0.06-0.13). There were also no signiﬁcant group differences as measured with the disease-speciﬁc measures device acceptance (A =
j0.37; p = .82), shock anxiety (A = 0.21; p = .70), and ICD-related concerns (A = j0.08; p = .90). No differences between treatment
completers and noncompleters were observed on any of the measures. Conclusions: In this Web-based intervention trial, no sig-
niﬁcant intervention effects on anxiety, depression, health-related quality of life, device acceptance, shock anxiety, or ICD-related
concerns were observed. A more patient tailored approach targeting the needs of different subsets of ICD patients may be warranted.
Trial registration: clinicaltrials.gov. Identiﬁer: NCT00895700. Key words: implantable cardioverter-deﬁbrillator, anxiety, depression,
quality of life, Web-based behavioral treatment.
CBT = cognitive behavioral therapy; FSAS = Florida Shock Anxiety
Scale; GAD-7 = General Anxiety Disorder scale; ICD = implantable
cardioverter-deﬁbrillator; ICDC = ICD Patient Concerns;MCS = Mental
Component Scale; NYHA = New York Heart Association functional
class; PCS = Physical Component Scale.
INTRODUCTION
The implantable cardioverter-deﬁbrillator (ICD) is the treat-ment of choice for the primary and secondary prevention of
life-threatening ventricular tachyarrhythmias (1Y4). In Europe,
800,000 patients live with a cardiovascular implantable elec-
tronic device, such as the ICD (5). Since emotional distress in
ICD patients has been linked to risk for ventricular tachyar-
rhythmias and mortality (6,7), there is increasing interest in the
well-being of ICD patients (8).
Previous trials have shown that cognitive behavioral therapy
(CBT) reduces anxiety and depression in ICD patients (9,10).
However, these trials are characterized by relatively small sam-
ple sizes, large dropout rates, and potential selection bias (9). To
make behavioral treatment accessible to a large group of ICD
patients, we developed the Web-based Distress Management
Program for Implantable Cardioverter Deﬁbrillator (WEBCARE)
patients (11). AWeb-based approach requires no extra hospital
visits, as patients are able to access treatment in their own time
and at a place that is convenient to them. The use of the Web-
based approach for treatment of psychological distress has
shown promising results in both healthy and chronically ill
patients (12). The WEBCARE intervention is a 12-week ﬁxed,
six-lesson behavioral treatment based on the problem-solving
principles of CBT.
The aims of the current study were to investigate (1) the
short-term effectiveness of the WEBCARE intervention on symp-
toms of anxiety, depression, health-related quality of life, device
acceptance, shock anxiety, and ICD-related concerns 3 months
postimplant, and (2) the sample characteristics of patients who
elected to participate in the WEBCARE trial.
METHODS
Study Design
Within the ﬁrst year after trial inclusion, patients were asked to complete
a set of standardized and validated questionnaires at four time points (i.e.,
baseline and 3, 6, and 12 months). For the current study, only the baseline and
3-month follow-up data were used, as the short-term effectiveness of the in-
tervention was assessed. Patients’ clinical characteristics were assessed at the
time of implantation, whereas data on ICD therapy, captured from the infor-
mation saved by the ICD, were available throughout the follow-up period. A
detailed description of the trial design has been published previously (11). The
trial was designed to ‘‘treat’’ existing distress but also to prevent the onset of
distress. The sample size was calculated based on the expected difference in
anxiety (the primary study outcome). Based on a power of 0.80 (two-tailed
test) and an > of .05, we needed 175 participants in each condition to show an
effect size of 0.30, requiring a total sample of 350 patients. The study protocol
was approved by the medical ethics committees of the participating hospitals,
and the trial was registered on http://www.ClinicalTrials.gov (NCT00895700).
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Participants
The study cohort comprised consecutive patients from six Dutch referral
hospitals (Amphia Hospital, Breda; Canisius-Wilhelmina Hospital, Nijmegen;
Catharina Hospital, Eindhoven; Erasmus Medical Center, Rotterdam; Onze Lieve
Vrouwe Gasthuis Hospital, Amsterdam; Vlietland Hospital, Schiedam) who were
admitted for a ﬁrst-time ICD implant between April 2010 and February 2013.
Inclusion criteria were ﬁrst-time ICD implant and age between 18 and 75 years.
Exclusion criteria were signiﬁcant cognitive impairments (e.g., dementia), his-
tory of psychiatric illness other than affective/anxiety disorders, life-threatening
comorbidities (e.g., cancer), life expectancy less than 1 year, being on the waiting
list for heart transplantation, lack of Internet/computer skills, and insufﬁcient
knowledge of the Dutch language. Patients were included regardless of their
psychological distress levels (e.g., anxiety and depression), as WEBCARE was
designed as a (primarily anxiety) prevention and reduction trial. For this reason,
distress was not an eligibility criterion for trial participation.
Procedure
Patients were approached by the ICD nurse or technician before or brieﬂy
after ICD implantation. The inclusion criteria were checked by reviewing
patients’ medical records and by checking them in person with the patient
(e.g., availability and use of the Internet). Patients were informed about the
study both orally and in writing. If patients met the inclusion criteria and none
of the exclusion criteria and were willing to participate, they signed the in-
formed consent form and were provided with the ﬁrst set of questionnaires
(baseline). After completing the questionnaires, patients returned them in a
preaddressed, stamped envelope to Tilburg University, which served as core
laboratory for the trial. If the questionnaires were not returned within 2 weeks,
patients received up to three reminder telephone calls. For follow-up assess-
ment, patients received per mail the second set of questionnaires and were asked
to return these to Tilburg University within 1 week. If patients did not return
the questionnaire within the ﬁrst week, they received up to three reminder
telephone calls.
Randomization
Upon returning the baseline questionnaires and before opening the enve-
lope, patients were randomized on a 1:1 basis (by drawing a sealed envelope for
each patient containing the condition) to either theWEBCARE or the usual care
group. Block randomization by computer was used, randomizing 20 patients
per hospital, at each time point. The randomization list was generated by an
independent, blinded, statistician and sealed by a research assistant. The health
care providers were blinded to assignment to WEBCARE versus usual care.
Blinding of participants and coaches (master-level psychologists who were
trained according to a standardized protocol to provide online feedback to
patients) was not possible given the nature of the study.
Intervention
Patients in the WEBCARE group received a 12-week ﬁxed, online course
consisting of six lessons, based on problem-solving therapy, in addition to usual
care. The problem-solving approach was based on the self-examination ther-
apy of Bowman et al. (13) in combination with cognitive behavioral compo-
nents. The intervention was based on the course ‘‘Everything under control’’
(Alles Onder Controle) (14). The online course has been evaluated within a
physically healthy, depressed population and has shown to be effective in re-
ducing psychological distress (14,15). For the current study, the online course
was modiﬁed for ICD patients (in collaboration with the Dutch ICD patient
organization STIN) to take into account issues pertinent to this speciﬁc target
group. The major modiﬁcations included the addition of a lesson on psycho-
education with respect to living with an ICD and adaptation of the cases
that are presented in relation to the homework assignments for patients to
ICD-speciﬁc cases to enhance patient identiﬁcation and adherence. A detailed
description of the course has previously been published (14,16). Brieﬂy, the
ﬁrst lesson was educational (psychological problems experienced by ICD pa-
tients), with no additional homework assignments. As of Lesson 2, a more
active problem-solving approach was introduced. Patients were asked to list what
they considered important in their lives and which problems they were experienc-
ing at this time and to label the problems as either a) important problems that can
be solved, b) unimportant problems that can be solved, or c) problems that can-
not be solved. In Lesson 3, patients were asked to choose one problem that they
labeled as an ‘‘important problem that can be solved’’ and actively work on this
problem using problem-solving techniques. In Lesson 4, patients were asked
to choose a problem from the ‘‘unimportant problems that can be solved’’ and
actively work on these using techniques like engaging in positive thinking, stop
ruminating, and so on. In Lesson 5, patients worked with problems that cannot
be solved (here was mostly mentioned ‘‘not being able to drive within the two
months post ICD implantation’’). Patients were taught how to deal with these
problems but not how to solve them. In Lesson 6, the last lesson, patients were
asked to make a future plan of which goals they wanted to achieve in the future
and how they would go about this. All patients also received a CD with relaxa-
tion training exercises. In addition, with every lesson, patients were able to read
about the experiences of other ICD patients and how they manage their lives
and problems.
Patients were allowed to complete the six lessons in their own time and
pace. Patients could only proceed to the next lesson if they had ﬁnished the
former and sent the homework assignment to their coach (who provided feed-
back online). Patients received automatic reminder e-mails every 2 weeks if
they did not submit their homework; their account was closed after 12 weeks.
Patients in the control group received standard care from the hospital,
equivalent to patients not enrolled in the study. No restrictions were applied
to care as usual.
Measures
Information on demographic and clinical variables (Table 1) was obtained
via self-report or patients’ medical records. The Charlson Comorbidity Index
(17) was calculated based on self-report data and information from patients’
medical records. All baseline questionnaires were ﬁlled in postimplantation
(mean = 9.9 days postimplant). To explore whether the prevalence of anxiety
and depression may vary depending on the instrument used, we administered
multiple questionnaires to assess anxiety and depression.
Generic Outcome Measures
Anxiety
The seven-item General Anxiety Disorder scale (GAD-7) was used to assess
symptoms of anxiety. The GAD-7 consists of seven items (e.g., ‘‘Feeling nervous,
anxious, or on edge’’) that are rated on a 4-point Likert scale ranging from
0 (not at all) to 3 (almost every day) (18). The total score ranges from 0 to 21,
with a higher score indicating higher anxiety levels. A cutoff score of at least 10
is used as an indication of probable clinical levels of anxiety. The internal con-
sistency of the GAD-7 is good with a Cronbach > of .92 (18).
The State version of the State-Trait Anxiety Inventory was also adminis-
tered to assess anxiety (19). It consists of two 10-item subscales measuring the
presence (e.g., ‘‘I am worried’’) and absence of anxiety (e.g., ‘‘I feel calm’’).
Items are answered on a 4-point Likert scale ranging from 0 (not at all) to 4
(very much so). The total score ranges between 20 and 80, with a higher score
indicating higher anxiety levels and 40 or higher indicating probable clinical
anxiety levels (19).
All patients also completed the seven-item anxiety subscale (e.g., ‘‘I feel
tense or wound up’’) from the Hospital Anxiety and Depression Scale (20,21).
Items are answered on a 4-point Likert scale from 0 to 3 (score range of 0Y21),
with a higher score indicating more symptoms of anxiety and 8 or higher
indicating the presence of probable clinical levels of anxiety (20).
Depression
The Patient Health Questionnaire (22) is a self-administered version of
the PRIME-MD comprising nine items that are evaluated on a 4-point Likert
scale (e.g., ‘‘Little interest or pleasure in doing things’’) (score range, 0Y27).
A higher score indicates higher depression symptom severity and 10 or
higher indicates the presence of likely depressive symptoms (22). The scale taps
into the nine diagnostic criteria for DSM-IV depressive disorders. The Patient
Health Questionnaire-9 has excellent reliability with a Cronbach > of .91 (23)
and good validity (22),
All patients also completed the seven-item depression subscale (e.g., ‘‘I feel
as if I am slowed down’’) from the Hospital Anxiety and Depression Scale
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TABLE 1. Baseline Demographic and Clinical Variables for the Total Sample and Stratiﬁed by Treatment Condition
Total (n = 289) WEBCARE (n = 146) Usual Care (n = 143) p
Demographics
Age, means (SD), y 58.52 (9.89) 58.23 (9.87) 58.63 (10.19) .73
Sex (male) 235 (81.3) 120 (82.2) 115 (80.4) .70
Partner (yes), n = 288 244 (84.7) 124 (84.9) 120 (84.5) .92
Education (high), n = 285 208 (73.0) 106 (73.1) 102 (72.9) .96
Working (yes), n = 288) 141 (49.0) 68 (46.6) 73 (51.4) .41
Smoking (yes), n = 288) 40 (13.9) 21 (14.4) 19 (13.4) .81
BMI, n = 287, means (SD), kg/m2 28.09 (10.74) 27.76 (11.00) 28.43 (10.46) .60
Children (yes), n = 287 237 (82.6) 125 (85.6) 112 (82.6) .17
Hospital .93
Amphia 64 (22.1) 34 (23.3) 30 (21.0)
Canisius 22 (7.6) 10 (6.8) 12 (8.4)
Catharina 119 (41.2) 60 (41.1) 59 (41.3)
Erasmus 47 (16.3) 22 (15.1) 25 (17.5)
OLVG 24 (8.3) 14 (9.6) 10 (7.0)
Vlietland 13 (4.5) 6 (4.1) 7 (4.9)
Clinical
Secondary indication 90 (31.1) 39 (26.7) 51 (35.7) .10
PMI 148 (51.2) 73 (50.0) 75 (52.4) .68
PPCI 82 (28.4) 30 (20.5) 52 (36.4) .003
CABG 51 (17.6) 23 (15.8) 28 (19.6) .39
Structural heart diseasea 12 (4.2) 6 (4.1) 6 (4.2) .97
History of arrhythmia 66 (22.8) 37 (25.3) 29 (20.3) .31
Heart rate, n = 284, means (SD) 71.71 (16.15) 71.76 (16.84) 71.66 (15.48) .96
QRS 9120, n = 287 128 (44.6) 59 (41.0) 69 (48.3) .22
BBB, n = 287 109 (38.0) 52 (36.1) 57 (39.9) .51
Heart failure 157 (54.3) 78 (53.4) 79 (55.2) .76
NYHA III/IV, n = 232 45 (19.4) 20 (17.4) 25 (21.4) .44
LVEF e35 184 (63.7) 87 (59.6) 97 (67.8) .15
Comorbidity
Anemia 16 (5.5) 7 (4.8) 9 (6.3) .58
CVA 11 (3.8) 6 (4.1) 5 (3.5) .79
TIA 14 (4.8) 8 (5.5) 6 (4.2) .61
COPD 23 (8.0) 13 (8.9) 10 (7.0) .55
Diabetes 42 (14.5) 18 (12.3) 24 (16.8) .28
Dysplipidemia 62 (21.5) 30 (20.5) 32 (22.4) .71
Hypertension 64 (22.1) 35 (24.0) 29 (20.3) .45
Malignancy 11 (3.8) 6 (4.1) 5 (3.5) .79
PAD 12 (4.2) 9 (6.2) 3 (2.1) .08
Creatinine, n = 254, means (SD) 94.97 (37.73) 94.74 (29.11) 95.25 (45.84) .92
CCI, means (SD) 1.69 (1.04) 1.60 (1.06) 1.78 (1.02) .15
Cardiac medication
Amiodarone 26 (9.0) 12 (8.2) 14 (9.8) .64
A-Blocker 237 (82.0) 117 (80.1) 120 (83.9) .40
Aspirin 139 (48.1) 70 (47.9) 69 (48.3) .96
Class I agents 5 (1.7) 1 (0.7) 4 (2.8) .17
Sotalol 9 (3.1) 4 (2.7) 5 (3.5) .71
Nitrates 36 (12.5) 21 (14.4) 15 (10.5) .32
Calcium antagonist 19 (6.6) 10 (6.8) 9 (6.3) .85
Digoxin 16 (5.5) 11 (7.5) 5 (3.5) .13
(Continued on next page)
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(20,21). Items are answered on a 4-point Likert scale from 0 to 3, with a score
range of 0 to 21, and the reliability/validity of this measure has been demon-
strated in cardiac patients (24). A predeﬁned cutoff score of 8 or higher indi-
cates probable clinical levels of depressive symptoms (20).
Health-Related Quality of Life
The Dutch version of the Short-Form Health Survey 12 was administered
to assess health-related quality of life (25). The 12 items contribute to physical
and mental health status that are summed into a Physical Component Scale
(PCS) and Mental Component Scale (MCS) score (score range, 0Y100), with
a higher score indicating better functioning. The Short-Form Health Survey 12
has previously been used in the ICD population (26) and has shown to be a
valid and reliable instrument (27).
Disease-Speciﬁc Outcome Measures
Device Acceptance
Device acceptance was assessed with the Florida Patient Acceptance Sur-
vey (28). The abbreviated 12-item version was used, which has been validated
in Dutch (29) and Danish (30) ICD patients (e.g., ‘‘I have returned to a full
life’’). Items are rated on a 5-point Likert scale ranging from 0 (strongly dis-
agree) to 4 (strongly agree), with a total score of 0 to 100, with a higher score
indicating higher acceptance. The Florida Patient Acceptance Survey has
shown to be internally consistent with Cronbach > of .82 and .85 for Dutch (29)
and Danish (30) ICD populations.
Shock Anxiety
The Florida Shock Anxiety Scale (FSAS) was used to assess shock an-
xiety (31). The FSAS is a 10-item disease-speciﬁc questionnaire with items
(e.g., ‘‘I worry about the ICD ﬁring and creating a scene’’) rated on a 5-point
Likert scale ranging from 1 (never) to 5 (always), with higher scores indicating
a higher level of shock anxiety (32). A total scale score was used in the cur-
rent study. The FSAS has proven to be a reliable measure with a Cronbach
> of .89 (31).
Patient Concerns About the ICD
To measure patients’ concerns about the ICD, the Dutch version of the
ICD Patient Concerns (ICDC) questionnaire was used (33). The ICDC con-
sists of eight items (e.g., ‘‘I’m worried that my ICD will ﬁre’’) that are rated on
a 5-point Likert scale ranging from 0 (not at all) to 4 (very much), with a score
range of 0 to 32, with a higher score indicating higher levels of concerns. The
ICDC is an internally consistent scale with a Cronbach > of .91 (33)
Statistical Analyses
Baseline
Discrete variables were compared using the W2 test and are presented as
percentages. Continuous variables were compared using the Student’s t test for
independent samples and are presented as mean values and standard devia-
tions. The number of missing data (for randomized patients) was relatively
small, ranging between 0 and 2% for demographic and psychological variables
and between 0 and 20% for clinical measures, with most patients missing
information on New York Heart Association (NYHA) functional class, which
is a measure of the severity of heart failure. If a questionnaire had less than
80% missing data, data were imputed using the mean score of the patient on
the completed items.
Follow-Up
To perform the analysis according to the intention-to-treat principle, mean
imputation was performed for missing item scores (G80% of items missing),
while multiple imputation was carried out, with 20 iterations, for total miss-
ing scores using the default option for multiple imputation in SPSS. To ana-
lyze intervention effects, linear regression was performed, adjusting for baseline
distress. To compare intervention effects for treatment completers versus non-
completers, univariable and multivariable linear regressions were performed ad-
justing for age, sex, education level, left ventricular ejection fraction, QRS width,
Charlson Comorbidity Index, (17), and ICD indication (primary versus second-
ary). Cohen d was calculated to indicate the magnitude of the intervention effect
(0.20 = small; 0.50 = medium; 0.80 = large) (34).
A p G .05 indicated statistical signiﬁcance; all tests were two tailed. All
data were analyzed using SPSS Statistics 19.0 for Windows.
RESULTS
Sample Characteristics
A total of 1024 consecutive patients implanted between April
2010 and February 2013 were screened for study participation
(Fig. 1), of which 492 (48%) were excluded because they did
TABLE 1. (Continued)
Total (n = 289) WEBCARE (n = 146) Usual Care (n = 143) p
ACE inhibitor 180 (62.3) 82 (56.2) 98 (68.5) .03
ARB 46 (15.9) 29 (19.9) 17 (11.9) .06
Spironolactone 70 (24.2) 34 (23.3) 36 (25.2) .71
Diuretics 147 (50.9) 72 (49.3) 75 (52.4) .59
Statins 182 (63.0) 92 (63.0) 90 (62.9) .99
Anticoagulants 127 (43.9) 58 (39.7) 69 (48.3) .14
Thyrax 5 (1.7) 4 (2.7) 1 (0.7) .18
Psychotropics 20 (6.9) 13 (8.9) 7 (4.9) .18
Antidepressants 7 (2.4) 3 (2.1) 4 (2.8) .68
Anxiolytics 17 (5.9) 11 (7.5) 6 (4.2) .23
Hypnotics 10 (3.5) 6 (4.1) 4 (2.8) .54
WEBCARE = Web-based Distress Management Program for Implantable Cardioverter Deﬁbrillator; M = mean; SD = standard deviation; BMI = body mass index;
OLVG = Onze Lieve Vrouwe Gasthuis; PMI = previous myocardial infarction; PPCI = previous percutaneous coronary intervention; CABG = coronary artery bypass
grafting; BBB = bundle branch block; NYHA = New York Heart Association functional class; LVEF = left ventricular ejection fraction; CVA = cerebrovascular
accident; TIA = transient ischemic attack; COPD = chronic obstructive pulmonary disease; PAD = peripheral artery disease; CCI = Charlson Comorbidity Index.
Results are presented as total number (%); continuous variables are presented as means (SD).
aDilated cardiomyopathy, hypertrophic cardiomyopathy, arrhythmogenic right ventricular cardiomyopathy, congenital heart disease.
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not meet the inclusion criteria (i.e., lack of Internet [53%],
age 975 years [30%], language barrier [6%]). Of the remaining
532 patients, 192 (36%) refused to participate (due to time con-
straints, having to deal with a lot of issues, not needing psycho-
logical help, not interested in participating in clinical studies,
too much work/too sick) and 51 (10%) patients did not return
the baseline measures, leaving 289 (54%) patients for random-
ization to the WEBCARE (n = 146) versus usual care group
(n = 143). Of the 146 patients who were randomized to the
WEBCARE group, 34 (23%) completed the full six lessons of
the intervention (see Fig. 1 for a detailed description). Reasons
for dropout most often given by patients were as follows: tech-
nical problems with the computer (21%), time constraints (15%),
feeling ﬁne, and not needing additional support (11%). A de-
tailed description of attrition and adherence in the WEBCARE
cohort is provided elsewhere (35).
Nonparticipants
Patients who did not return the baseline questionnaires (n = 51)
or were excluded (not randomized) from current analyses did
not differ systematically on demographic variables. However, pa-
tients who were not randomized were more likely to have NYHA
class III/IV (p = .045) and peripheral artery disease (p = .022), and
more likely to use psychotropic medication (p G. 001; anxiolytics
[p = .004] and hypnotics [p = .010]). Of the 192 patients who
fulﬁlled the inclusion criteria but refused to participate, 60 signed
consent and gave permission for medical record screening at the
time of implantation. These patients were older (60.26 T 1.80
versus 58.16 T 10.30; p = .042) and were more likely to have
NYHA class III/IV (39.0% versus 21.3%; p = .013), previous
myocardial infarction (76.6% versus 50.1%; p = .001), coronary
artery bypass grafting (34.0% versus 19.2%; p = .019), peripheral
artery disease (13.6% versus 5.3%; p = .018), or an ICD with car-
diac resynchronization therapy (57.9% versus 25.9%; p G .001)
as compared with patients who signed informed consent form
for study participation (n = 340).
Baseline Characteristics
The mean (standard deviation) age of the total sample was
58.5 (9.9) years, and 81% of the sample were men (Table 1).
The WEBCARE and usual care groups did not differ on demo-
graphic characteristics, but the usual care group was more likely
to have been treated with percutaneous coronary intervention
(36.4% versus 20.5%; p = .003) and angiotensin-converting en-
zyme inhibitors (68.5% versus 56.2%; p = .031) as compared
with the WEBCARE group. No other systematic differences be-
tween groups were observed (Table 1).
There were no systematic differences on any of the psycho-
logical measures between both groups at baseline (Table 2).
The prevalence ranged between 11% and 30% for anxiety and
Figure 1. Flowchart patient recruitment.
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between 13% and 21% for depression, indicating great variability
depending on the instrument used. Given that no standardized
cutoffs are available for the disease-speciﬁc measures, we could
not present prevalence rates for these measures.
Effects of the Intervention on General Distress
and Health-Related Quality of Life
No signiﬁcant differences between the WEBCARE and usual
care groups were observed at 3-month follow-up on anxiety
(A = 0.35; p = .32), depression (A =j0.01; p = .98), or health-
related quality of life (MCS: A = 0.19; p = .86; PCS: A = 0.58;
p = .60). A similar decrease in anxiety and depression was ob-
served in both groups, as was an increase in both mental and
physical health-related quality of life (Fig. 2). The effect sizes
for these measures were 0.13, 0.003, 0.02, and 0.06, indicating
a negligible effect. Comparing treatment completers versus non-
completers also revealed no differences in anxiety (A = 0.52;
p = .50), depression (A = j0.12; p = .88), and health-related
quality of life (MCS: A = 0.22; p = .91; PCS: A = 0.54; p = .80)
between groups. Subgroup analyses were performed for patients
with increased distress at baseline, but no signiﬁcant effects were
observed (data not shown).
Effects of the Intervention on Device-Related Concerns
No signiﬁcant differences between the WEBCARE and usual
care groups were observed at 3 months on any of the disease-
speciﬁc measures: device acceptance (A =j0.37; p = .82), shock
anxiety (A = 0.21; p = .70), and ICD-related concerns (A =j0.08;
p = .90). The effect sizes for the three outcome measures were
0.03, 0.05, and 0.02, respectively, indicating a negligible effect.
No signiﬁcant differences were observed between completers
and noncompleters on any of the above-mentioned measures:
device acceptance (A = 2.69; p = .39), shock anxiety (A = 26;
p = .81), and ICD-related concerns (A = j0.21; p = .86). Sub-
group analyses of patients with increased concerns at baseline
showed no signiﬁcant effects of the intervention (data not
shown; Fig. 3).
DISCUSSION
To our knowledge, this is the largest e-health trial targeting
emotional distress in cardiac patients in general and in ICD
patients in particular. Patients in the WEBCARE group did not
report better outcomes 3 months postimplant as compared with
patients in the usual care group, indicating no effect of the in-
tervention on the short term. Patients who completed the full six
lessons of the treatment as compared with patients who did not
initiate or failed to complete the six lessons did not differ sig-
niﬁcantly on any of the generic or disease-speciﬁc, patient-
reported outcomes.
Patients included in the WEBCARE trial were predomi-
nantly male, with a higher educational level and a partner. In
addition, mean scores on psychological measures (e.g., anxiety
and depression) were relatively low at the time of implant. These
ﬁndings suggest that we may not have been successful in reach-
ing those patients who might have beneﬁted the most (e.g.,
female patients and patients with high distress levels). Prev-
iously female-speciﬁc interventions have been suggested by others
(36). Although in the current study, no signiﬁcant intervention
TABLE 2. Psychological Proﬁle and Health-Related Quality of Life for the Total Sample and Stratiﬁed by Treatment Condition at Baseline
Total (n = 289) WEBCARE (n = 146) Usual Care (n = 143) p
Generic measures
Anxiety
GAD-7, n = 288 4.30 (4.54) 4.57 (5.02) 4.03 (3.98) .31
HADS-A, n = 288 4.59 (3.26) 4.91 (3.39) 4.27 (3.09) .09
STAI-S, n = 288 35.24 (10.32) 35.57 (10.65) 34.90 (9.99) .59
Depression
PHQ-9 5.65 (4.83) 5.93 (5.11) 5.37 (4.53) .32
HADS-D, n = 288 3.52 (3.01) 3.55 (3.02) 3.49 (3.02) .89
Health-related quality of life
SF-12
MCS 44.29 (11.08) 43.83 (11.28) 44.76 (10.89) .48
PCS 40.57 (10.44) 40.19 (10.55) 40.96 (10.35) .53
Disease-specific measures
FPAS, n = 288 66.53 (11.19) 66.36 (11.99) 66.71 (10.35) .79
FSAS, n = 287 16.37 (5.74) 16.73 (6.13) 16.00 (5.32) .28
ICDC, n = 287 6.33 (6.48) 6.53 (6.68) 6.12 (6.28) .59
WEBCARE = Web-based Distress Management Program for Implantable Cardioverter Deﬁbrillator; GAD-7 = General Anxiety Disorder scale; HADS (A-D):
Hospital Anxiety and Depression Scale; STAI-S = State-Trait Anxiety Inventory ScaleYState Version; PHQ-9 = Patient Health Questionnaire; SF-12 = Short-Form
Health Survey 12; MCS = Mental Component Scale; PCS = Physical Component Scale; FPAS = Florida Patient Acceptance Scale; FSAS = Florida Shock Anxiety
Scale; ICDC = ICD Patient Concerns.
Results are presented as mean (standard deviation).
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effects were observed in patients with increased distress at base-
line, other studies did demonstrate some effects of CBT in this
subgroup (9).
The observed discrepancy between prevalence rates of an-
xiety and depression depending on the self-report measure used
has, to date, not been addressed in ICD patients. The preval-
ence rates of anxiety and depression ranged between 11% and
30% and 13% and 21%, respectively, depending on which in-
strument was used. This ﬁnding underlines that anxiety and de-
pression measures cannot necessarily be used interchangeably
and that the choice of instrument may have implications for the
screening of and treatment for patients in clinical practice. Fur-
ther research is warranted to critically evaluate and compare cur-
rent instruments to provide recommendations with respect to
which instrument might be preferred and for which purpose
(i.e., as a screening tool or an outcome measure) (37).
Generally, behavioral interventions in ICD patients have
shown promising results in terms of reducing distress (9,10).
Although WEBCARE does not conﬁrm these ﬁndings, previ-
ous trials were based on face-to-face treatment rather than a
Web-based approach, and included only patients with increased
distress levels at baseline. Because patients were included in the
WEBCARE trial regardless of their distress level at baseline,
this may have inﬂuenced both the effect of the intervention and
treatment adherence. A low distressed population may not feel
the need to complete the full six-lesson course. Moreover, Web-
based approach may likely only appeal to a subgroup of patients
who feel comfortable with such an approach and are willing to
work on their problems via the computer. Despite the well-
known beneﬁts of a Web-based approach (high accessibility,
ability to reach underserved groups, etc), the issue of reaching
only particular subgroups of patients who are interested in
using Internet for health care purpose has been described by
others (38,39). Time constrains, competing interests, perception
of limited worth of the intervention, and anxiety about spending
time on the computer were previously described as factors that
contributed to an increased attrition in an online treatment for
older adults with comorbid cardiac disease (40). To a degree, this
is in line with the reasons provided by WEBCARE patients for
prematurely terminating the treatment. In addition, the design of
the WEBCARE trial and the intervention might have been in-
adequate to promote adherence (e.g., too soon, too long, and too
complicated), and the high attrition rate might have inﬂuenced
the effect sizes related to the intervention. A detailed description
of attrition and adherence in the WEBCARE trial is provided
elsewhere (35).
To increase adherence and likely treatment effects, future re-
search should focus on understanding the reasons for nonadherence
Figure 2. Mean scores on generic measures at baseline and 3 months stratiﬁed
by group. Scores on the anxiety scale can range between 0 and 21; scores on the
depression scale can range between 0 and 27; scores on the PCS and MCS
scales can range between 0 and 100. SDs for baseline means are presented in
Table 2; SDs at follow up are for the WEBCARE and usual care groups,
respectively: 4.0 and 3.6 (anxiety), 4.3 and 3.9 (depression), 10.17 and 10.39
(MCS), and 10.72 and 11.29 (PCS). PCS = Physical Component Scale; MCS =
Mental Component Scale, SD = standard deviation; WEBCARE =WEB-Based
Distress Management Program for Implantable Cardioverter Deﬁbrillator.
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and developing more patient tailored Web-based approaches that
will better meet patients’ needs. As with previous trials in cardiac
patients,WEBCARE conﬁrms that also aWeb-based intervention is
unlikely to be a ‘‘one size ﬁts all’’ approach, as participants were
predominantly highly educated men. Furthermore, the timing of the
intervention might be essential, with WEBCARE being offered al-
ready within the ﬁrst 2 weeks postimplant. This might have been
too soon, as patients are preoccupied with practical issues (e.g.,
driving restrictions, physical impairments, etc) and might not be
ready to start working on their psychological problems. One way
of circumventing premature intervention in patients who do not
really need it would be to include a ‘‘watchful waiting period,’’ as
has been done in some of the collaborative care trials in patients
with acute coronary syndrome, such as the COPES (41) and
CODIACS trial (42).
Limitations and Strengths
Most participants were highly educated men who might have
been more motivated to participate, leading to a potential selec-
tion bias. A signiﬁcant number of patients were excluded due
to not meeting the inclusion criteria or refusing to participate,
jeopardizing generalizability, as results showed systematic dif-
ferences on demographic and clinical characteristics between
these groups and patients who participated. This may suggest a
selection bias towardmore healthy patients. The follow-up period
of 3monthswas relatively short, and thus, we are not able tomake
any conclusions about potential long-term effects.
However, this is the ﬁrst trial targeting distress in ICD popu-
lation using a Web-based approach. In addition, we included a
broad range of outcome measures and, thus, were able to tap into
disease-speciﬁc distress and clinical change postintervention.
This approach has recently been advocated by others (43), as it
remains unclear whether generic measures are sensitive enough
to detect changes in psychological distress posttreatment. Our
results did not differ dependent on the outcome measure used
(i.e., disease-speciﬁc versus generic). However, our ﬁndings dem-
onstrate that the notion of ‘‘one size ﬁts all’’ does not apply to a
Web-based approach targeting distress in ICD patients, but may
only be appropriate for a particular subset of patients.
Clinical and Research Implications
The ﬁndings of the current study are informative for de-
signing future psychological and behavioral intervention trials
in ICD patients, as we have gained a better understanding of the
demographic, psychological, and clinical proﬁle of patients
who are (less) willing to participate in online behavioral in-
terventions. Future research is warranted to look into patients’
speciﬁc needs and evaluate the appropriate timing of the inter-
vention. A collaborative, stepped-care approach that includes a
watchful waiting period before the intervention is offered, with
serial evaluations to monitor distress over time with potential to
intervene when needed, and that is targeted to patients’ needs and
preferences, may be one of the ways forward (9). Blended-care
treatments where face-to-face and Web-based approaches are
integrated may comprise another avenue to pursue. With this
Figure 3. Mean scores on disease-speciﬁc measures at baseline and 3 months
stratiﬁed by group. Scores on device acceptance scale can range between 0 and
100; scores on shock anxiety scale can range between 10 and 50; scores on ICD
concerns scale can range between 0 and 32. SDs for baseline means are
presented in Table 2; SDs at follow-up are for the WEBCARE and usual care
groups, respectively: 15.27 and 14.44 (device acceptance), 5.95 and 5.07 (shock
anxiety), and 6.2 and 6.0 (ICD concerns). ICD = implantable cardioverter-
deﬁbrillator; SD = standard deviation; WEBCARE = Web-based Distress
Management Program for Implantable Cardioverter Deﬁbrillator.
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knowledge, we will be able to further ‘‘customize’’ treatment to
patients’ needs and perhaps increase treatment adherence and
improve patients’ outcomes.
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